Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Companyâ€™s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	₩11,700.00	+7.54%	240,808
09/07/26	₩10,880.00	-0.82%	287,418
08/07/26	₩10,970.00	-6.24%	353,754
07/07/26	₩11,700.00	-2.09%	271,445
06/07/26	₩11,950.00	-5.46%	239,960

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
11,700.00 ^KRW	+7.54%		-7.44%	-40.15%

30/10/25	Onconic Therapeutics Q3 operating profit 8.3 billion won, swings to profit from year earlier	RE
14/04/25	Onconic Therapeutics Forecasts Posting Operating Loss Of 5.4 Billion Won For Year 2025	RE

Market Cap	531B 354M 309M 285M 264M 500M 33.74B 509M 3.41B 1.34B 16.62B 1.33B 1.3B 57.15B	P/E 2024	-16.5x	P/E 2025	56.2x
Enterprise Value	479B 319M 279M 257M 238M 451M 30.4B 458M 3.07B 1.21B 14.98B 1.2B 1.17B 51.49B	EV / Sales 2024	9.02x	EV / Sales 2025	15.3x
Free-Float	50.87%	Yield 2024 *	-	Yield 2025	-

30/10/25	Onconic Therapeutics Q3 operating profit 8.3 billion won, swings to profit from year earlier	RE
14/04/25	Onconic Therapeutics Forecasts Posting Operating Loss Of 5.4 Billion Won For Year 2025	RE
20/12/24	Onconic Therapeutics Shares Surge Nearly 71% on Kosdaq Debut	MT
12/12/24	Onconic Therapeutics Inc. has completed an IPO in the amount of KRW 20.15 billion.	CI

1 day	+7.54%
1 week	-7.44%
Current month	-13.01%
1 month	-25.81%
3 months	-44.68%
6 months	-47.42%
Current year	-40.15%

Onconic Therapeutics Inc. Stock

Stocks

A476060

KR7476060009

Biotechnology & Medical Research

Valuation: Onconic Therapeutics Inc.

Chart: Onconic Therapeutics Inc.

Latest news : Onconic Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Onconic Therapeutics Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	10,600	12,420
1 month	10,600	17,530
Current year	10,600	28,900
1 year	5,662.5	28,900
3 years	3,137.5	28,900
5 years	3,137.5	28,900
10 years	3,137.5	28,900

Manager	Title	Age	Since
Jon Kim CEO	Chief Executive Officer	59	01/01/2020
Jong-Gil Shin DFI	Director of Finance/CFO	50	01/01/2020
Jin-Seong Kim CTO	Chief Tech/Sci/R&D Officer	59	-

Director	Title	Age	Since
Jong-Gil Shin BRD	Director/Board Member	50	01/01/2020
Jon Kim BRD	Director/Board Member	59	01/01/2020
Jin-Woo Kim BRD	Director/Board Member	44	26/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/04/25	Jung-Hoon Kim	Fiscal year		50,000	0.4595%
18/04/25	Hyun-Joo Cha	Fiscal year	Chief Technology Officer	12,500	0.1149%
17/04/25	Jong-Gil Shin	Fiscal year	Chief Financial Officer	18,100	0.1663%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONIC THERAPEUTICS INC.	+7.54%	-7.44%	+92.99%	-	354M
ARGENX SE	-4.14%	-8.06%	+57.35%	+117.24%	54.63B
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+75.79%	+93.87%	54.88B
INSMED INCORPORATED	-2.24%	+3.59%	+19.60%	+466.72%	25.06B
BIONTECH SE	-1.60%	-6.21%	-19.69%	-14.84%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.88B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
EXELIXIS, INC.	-1.05%	+1.16%	+25.08%	+196.28%	14.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	15.36B
Average	+0.15%	-0.46%	+58.18%	+148.68%	24.16B
Weighted average by Cap.	-0.90%	-1.46%	+55.10%	+137.79%

	2024	2025
Net sales	14.84B 9.88M 8.64M 7.97M 7.36M 13.97M 942M 14.21M 95.26M 37.41M 464M 37.1M 36.3M 1.6B	53.39B 35.56M 31.1M 28.69M 26.5M 50.27M 3.39B 51.12M 343M 135M 1.67B 134M 131M 5.74B
Net income	-8.09B -5.39M -4.71M -4.35M -4.02M -7.62M -514M -7.75M -51.95M -20.4M -253M -20.24M -19.8M -871M	15.78B 10.51M 9.19M 8.48M 7.83M 14.86M 1B 15.11M 101M 39.79M 494M 39.47M 38.61M 1.7B
Net Debt	-42.69B -28.43M -24.87M -22.94M -21.19M -40.2M -2.71B -40.87M -274M -108M -1.34B -107M -104M -4.59B	-52.61B -35.04M -30.65M -28.27M -26.11M -49.54M -3.34B -50.37M -338M -133M -1.65B -132M -129M -5.66B